| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 43.000 +8.14% on 04/24/24 | | 57.900 -19.69% on 04/10/24 | -3.750 (-7.46%) since 04/02/24 |
| 3-Month | 43.000 +8.14% on 04/24/24 | | 110.000 -57.73% on 02/05/24 | -62.000 (-57.14%) since 02/02/24 |
| 52-Week | 43.000 +8.14% on 04/24/24 | | 166.980 -72.15% on 10/12/23 | -72.500 (-60.92%) since 05/02/23 |
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms,...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is...
| 3rd Resistance Point | 50.417 |
| 2nd Resistance Point | 48.583 |
| 1st Resistance Point | 47.667 |
| Last Price | 46.500 |
| 1st Support Level | 44.917 |
| 2nd Support Level | 43.083 |
| 3rd Support Level | 42.167 |
| 52-Week High | 166.980 |
| Fibonacci 61.8% | 119.620 |
| Fibonacci 50% | 104.990 |
| Fibonacci 38.2% | 90.360 |
| Last Price | 46.500 |
| 52-Week Low | 43.000 |